DOCSLIB.ORG

Parallel Import (PI) Licences Granted in May 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Parallel Import (PI) Licences Granted in May 2017 Parallel import (PI) licences granted in May 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 15184/1699 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.25% W/V EYE DROPS SOLUTION TIMOLOL 2.5 MILLIGRAMMES PER MILLILITRE POM PLPI 15184/1700 03/05/2017 LEXON (UK) LIMITED TIMOPTOL UNIT DOSE 0.5% W/V EYE DROPS SOLUTION TIMOLOL 0.5 MILLIGRAMMES PER MILLILITRE POM PLPI 16369/1716 03/05/2017 G-PHARMA LIMITED CELIPROLOL HYDROCHLORIDE 200MG TABLETS CELIPROLOL HYDROCHLORIDE 200.000 MILLIGRAMMES POM PLPI 21828/0717 03/05/2017 LANDMARK PHARMA LIMITED LEVOCARNITINE PAEDIATRIC 30% ORAL SOLUTION LEVOCARNITINE 30.00 PERCENT WEIGHT IN VOLUME POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED COLESTYRAMINE SUGAR FREE 4G-SACHET COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0768 03/05/2017 MPT PHARMA LIMITED QUESTRAN LIGHT 4G-SACHET POWDER FOR ORAL SUSPENSION COLESTYRAMINE 4.000 GRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER FLUTICASONE PROPIONATE 500.00 MICROGRAMMES POM PLPI 33532/0778 03/05/2017 MPT PHARMA LIMITED SERETIDE 500 ACCUHALER SALMETEROL XINAFOATE 0.0725 MILLIGRAMMES POM PLPI 33532/0779 03/05/2017 MPT PHARMA LIMITED TRIMIPRAMINE 25MG FILM-COATED TABLETS TRIMIPRAMINE MALEATE 34.9 MILLIGRAMMES POM PLPI 39352/0376 03/05/2017 KOSEI PHARMA UK LIMITED DESMOPRESSIN ACETATE 0.1MG TABLETS DESMOPRESSIN ACETATE 0.1 MILLIGRAMMES POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION CLIOQUINOL 1.000 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED FLUMETASONE PIVALATE/CLIOQUINOL 0.02% W/V / 1% W/V EAR DROPS SOLUTION FLUMETHASONE PIVALATE 0.020 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED LOCORTEN VIOFORM EAR DROPS SOLUTION CLIOQUINOL 1.000 PERCENT WEIGHT IN VOLUME POM PLPI 39352/0377 03/05/2017 KOSEI PHARMA UK LIMITED LOCORTEN VIOFORM EAR DROPS SOLUTION FLUMETHASONE PIVALATE 0.020 PERCENT WEIGHT IN VOLUME POM PLPI 40739/0131 03/05/2017 ENNOGEN HEALTHCARE LIMITED LOSEC 20 MG HARD GASTRO-RESISTANT CAPSULES OMEPRAZOLE 20.000 MILLIGRAMMES POM PLPI 20774/1515 04/05/2017 QUADRANT PHARMACEUTICALS LIMITED FLIXOTIDE 125 MICROGRAMS EVOHALER FLUTICASONE PROPIONATE 125.000 MICROGRAMMES POM PLPI 20774/1522 04/05/2017 QUADRANT PHARMACEUTICALS LIMITED FLIXOTIDE 250 MICROGRAMS EVOHALER FLUTICASONE PROPIONATE 250.000 MICROGRAMMES POM PLPI 20774/1527 04/05/2017 QUADRANT PHARMACEUTICALS LIMITED SERETIDE 500 ACCUHALER FLUTICASONE PROPIONATE 500 MICROGRAMMES POM PLPI 20774/1527 04/05/2017 QUADRANT PHARMACEUTICALS LIMITED SERETIDE 500 ACCUHALER SALMETEROL 50 MICROGRAMMES POM PLPI 33902/0635 04/05/2017 SAM PHARMA LIMITED PROSTAP SR DCS 3.75 MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLLEUPRORELIN ACETATE 3.75 MILLIGRAMMES POM PLPI 33902/0638 04/05/2017 SAM PHARMA LIMITED NEBIDO 1000 MG/4 ML, SOLUTION FOR INJECTION TESTOSTERONE UNDECANOATE 250.000 MILLIGRAMMES PER MILLILITRE POM PLPI 39467/0286 05/05/2017 PILSCO LIMITED NEBIVOLOL 2.5 MG TABLETS NEBIVOLOL 2.500 MILLIGRAMMES POM PLPI 15184/1692 10/05/2017 LEXON (UK) LIMITED PARACETAMOL 500MG SUPPOSITORIES PARACETAMOL 500.00 MILLIGRAMMES P PLPI 15184/1704 10/05/2017 LEXON (UK) LIMITED MERCAPTOPURINE 50MG TABLETS MERCAPTOPURINE 50.00 MILLIGRAMMES POM PLPI 16369/1717 10/05/2017 G-PHARMA LIMITED TROSYL NAIL SOLUTION TIOCONAZOLE 283 MILLIGRAMMES PER MILLILITRE POM PLPI 16369/1719 10/05/2017 G-PHARMA LIMITED XALACOM 50 MICROGRAMS/ML + 5 MG/ML EYE DROPS, SOLUTION LATANOPROST 50.00 MICROGRAMMES PER MILLILITRE POM PLPI 16369/1719 10/05/2017 G-PHARMA LIMITED XALACOM 50 MICROGRAMS/ML + 5 MG/ML EYE DROPS, SOLUTION TIMOLOL 5.00 MILLIGRAMMES PER MILLILITRE POM PLPI 18799/2989 10/05/2017 B AND S HEALTHCARE CLEXANE 40MG/0.4ML SYRINGE ENOXAPARIN SODIUM 40 MILLIGRAMMES POM PLPI 18799/2989 10/05/2017 B AND S HEALTHCARE ENOXAPARIN SODIUM 40MG/0.4ML SYRINGES ENOXAPARIN SODIUM 40 MILLIGRAMMES POM PLPI 19065/0501 10/05/2017 ECOSSE PHARMACEUTICALS LIMITED DIAMOX 250 MG TABLETS ACETAZOLAMIDE 250.00 MILLIGRAMMES POM PLPI 20492/0558 10/05/2017 CD PHARMA LIMITED DEXAMETHASONE 2 MG TABLETS DEXAMETHASONE 2 MILLIGRAMMES POM PLPI 20636/2906 10/05/2017 STAR PHARMACEUTICALS LIMITED DEXAFREE 1 MG/ML EYE DROPS, SOLUTION IN SINGLE-DOSE CONTAINER DEXAMETHASONE SODIUM PHOSPHATE 0.4372 MILLIGRAMMES POM PLPI 21828/0715 17/05/2017 LANDMARK PHARMA LIMITED NALCROM 100MG CAPSULES / SODIUM CROMOGLICATE 100MG CAPSULES SODIUM CROMOGLICATE 100.000 MILLIGRAMMES POM PLPI 33532/0757 17/05/2017 MPT PHARMA LIMITED AZITHROMYCIN 200MG/5ML SUSPENSION AZITHROMYCIN 200.00 MILLIGRAMMES PER 5 MILLILITRES POM * POM = Prescription Only Medicine 1 P = Pharmacy G = General Sale List Parallel import (PI) licences granted in May 2017 PL Number Grant Date Licence Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status* PLPI 33532/0757 17/05/2017 MPT PHARMA LIMITED ZITHROMAX 200MG/5ML SUSPENSION AZITHROMYCIN 200.00 MILLIGRAMMES PER 5 MILLILITRES POM PLPI 39467/0296 17/05/2017 PILSCO LIMITED AXYVEN XL 150 MG PROLONGED-RELEASE TABLETS VENLAFAXINE HYDROCHLORIDE 169.72 MILLIGRAMMES POM PLPI 45310/0004 17/05/2017 PUREPHARM LIMITED GENTAMICIN 0.3% W/V AND HYDROCORTISONE ACETATE 1% W/V EAR DROPS GENTAMICIN 0.3 PERCENT WEIGHT IN VOLUME POM PLPI 45310/0004 17/05/2017 PUREPHARM LIMITED GENTAMICIN 0.3% W/V AND HYDROCORTISONE ACETATE 1% W/V EAR DROPS HYDROCORTISONE ACETATE 1.000 PERCENT WEIGHT IN VOLUME POM PLPI 19488/1819 18/05/2017 S AND M MEDICAL LIMITED FORMOTEROL FUMARATE DIHYDRATE 6 MICROGRAM TURBOHALER FORMOTEROL FUMARATE DIHYDRATE 6.000 MICROGRAMMES POM PLPI 19488/1819 18/05/2017 S AND M MEDICAL LIMITED OXIS 6 TURBOHALER FORMOTEROL FUMARATE DIHYDRATE 6.000 MICROGRAMMES POM PLPI 20636/2879 18/05/2017 STAR PHARMACEUTICALS LIMITED ACETAZOLAMIDE 500 MG POWDER FOR SOLUTION FOR INJECTION ACETAZOLAMIDE 500.000 MILLIGRAMMES POM PLPI 20636/2879 18/05/2017 STAR PHARMACEUTICALS LIMITED DIAMOX SODIUM 500 MG POWDER FOR SOLUTION FOR INJECTION ACETAZOLAMIDE 500.000 MILLIGRAMMES POM PLPI 40593/0048 18/05/2017 SHAKESPEARE PHARMA LIMITED BETAGAN 0.5% W/V UNIT DOSE EYE DROPS, SOLUTION LEVOBUNOLOL HYDROCHLORIDE 0.500 PERCENT WEIGHT IN VOLUME POM PLPI 33532/0807 19/05/2017 MPT PHARMA LIMITED LERCANIDIPINE HYDROCHLORIDE 20 MG FILM-COATED TABLETS LERCANIDIPINE HYDROCHLORIDE 20.0 MILLIGRAMMES POM PLPI 15814/1327 24/05/2017 OPD LABORATORIES LIMITED PARNATE 10MG TABLETS / TRANYLCYPROMINE 10MG TABLETS TRANYLCYPROMINE 10.000 MILLIGRAMMES POM PLPI 20492/0561 24/05/2017 CD PHARMA LIMITED ADALAT 5MG SOFT CAPSULES NIFEDIPINE 5 MILLIGRAMMES POM PLPI 20492/0561 24/05/2017 CD PHARMA LIMITED NIFEDIPINE 5MG SOFT CAPSULES NIFEDIPINE 5 MILLIGRAMMES POM PLPI 33532/0777 24/05/2017 MPT PHARMA LIMITED ISRADIPINE 2.5MG TABLETS ISRADIPINE 2.500 MILLIGRAMMES POM PLPI 33532/0777 24/05/2017 MPT PHARMA LIMITED PRESCAL 2.5MG TABLETS ISRADIPINE 2.500 MILLIGRAMMES POM PLPI 33532/0804 24/05/2017 MPT PHARMA LIMITED TIMOLOL UNIT DOSE 0.25% W/V EYE DROPS SOLUTION TIMOLOL MALEATE 3.42 MILLIGRAMMES PER MILLILITRE POM PLPI 33532/0804 24/05/2017 MPT PHARMA LIMITED TIMOPTOL UNIT DOSE 0.25% W/V EYE DROPS SOLUTION TIMOLOL MALEATE 3.42 MILLIGRAMMES PER MILLILITRE POM PLPI 33532/0805 24/05/2017 MPT PHARMA LIMITED TIMOLOL UNIT DOSE 0.5% W/V EYE DROPS SOLUTION TIMOLOL MALEATE 6.83 MILLIGRAMMES PER MILLILITRE POM PLPI 33532/0805 24/05/2017 MPT PHARMA LIMITED TIMOPTOL UNIT DOSE 0.5% W/V EYE DROPS SOLUTION TIMOLOL MALEATE 6.83 MILLIGRAMMES PER MILLILITRE POM PLPI 15184/1694 25/05/2017 LEXON (UK) LIMITED OXIS TURBOHALER 6 INHALATION POWDER FORMOTEROL FUMARATE DIHYDRATE 6.000 MICROGRAMMES POM PLPI 15184/1698 25/05/2017 LEXON (UK) LIMITED VITAROS 3MG/G CREAM ALPROSTADIL 3 MILLIGRAMMES PER GRAM POM PLPI 19488/1809 25/05/2017 S AND M MEDICAL LIMITED IMIGRAN INJECTION SUMATRIPTAN SUCCINATE 8.4 MILLIGRAMMES POM PLPI 19488/1809 25/05/2017 S AND M MEDICAL LIMITED SUMATRIPTAN 6MG/0.5ML INJECTION SUMATRIPTAN SUCCINATE 8.4 MILLIGRAMMES POM PLPI 21828/0676 25/05/2017 LANDMARK PHARMA LIMITED ACETAZOLAMIDE MERCURY PHARMA 250MG TABLETS ACETAZOLAMIDE 250.000 MILLIGRAMMES POM PLPI 21828/0676 25/05/2017 LANDMARK PHARMA LIMITED DIAMOX 250MG TABLETS ACETAZOLAMIDE 250.000 MILLIGRAMMES POM PLPI 33532/0774 31/05/2017 MPT PHARMA LIMITED TRILEPTAL 60 MG-ML ORAL SUSPENSION OXCARBAZEPINE 60.000 MILLIGRAMMES PER MILLILITRE POM PLPI 33532/0806 31/05/2017 MPT PHARMA LIMITED LERCANIDIPINE HYDROCHLORIDE 10 MG FILM-COATED TABLETS LERCANIDIPINE HYDROCHLORIDE 10.00 MILLIGRAMMES POM PLPI 33902/0630 31/05/2017 SAM PHARMA LIMITED DUAC ONCE DAILY 10 MG/G + 30 MG/G GEL CLINDAMYCIN PHOSPHATE 12.8 MILLIGRAMMES PER GRAM POM PLPI 33902/0630 31/05/2017 SAM PHARMA LIMITED DUAC ONCE DAILY 10 MG/G + 30 MG/G GEL HYDROUS BENZOYL PEROXIDE 42.5 MILLIGRAMMES PER GRAM POM * POM = Prescription Only Medicine 2 P = Pharmacy G = General Sale List .
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • O SIEMSGLUSS IBERICA, S.A
    SIEMSGLUSS IBERICA, S.A. Product list G Memantine HCI Propylparaben Sodium Pharma APls Gemfibrozil Mepiramina Maleato R Gentian Powder Methoxsalen Ramipril Gentian Violet Methyl Nicotinate Ranitidin HCI Glibenclamide Methylprednisolone Base Rapamycin (Slrollrnus) Glimepiride Metimazole Resorcin A e Gluthatione reduced Metronidazol Resveratrol (Veri-Te®) 11 Alpha Hydroxyprogesterone Caffein Anhydrous Cyproterone Acetate Guaiacol Glyceril Ether Mexiletine HcI Rifampicin 17 Alpha Estradiol Calcipotriol Mieonazole Nitrate o H Roxythromycin Acetyl Salicylic Acid Canrenone Miltefosine Desonide Micronized Hydroquinone AcetylSpiramycin Cantharidin Minocycline HcI Dexamethasone BaseMicro Hyaluronic Acid Sodium Salt s Adapalene Captopril Minoxidil Seenidazol Dexamethasone Isonicotinate Miero Hydrochlorthiazide Amidopyrine Carbamazepine Mometasone Furoato Silver Sulfadiazine Dexamethasone Sodium Phosphate Hydrocortisone Acetate Micro Amikacin Sulphate Carbidopa Montelukast Sodium Simvastatine Dexketoprofen Trometamol Hydrocortisone BaseMicro Amiloride Carisoprodol Sodium Cefonicide Dextrometorphan Bromhidrate Hydroxyzine HcI N Amitriptyline HCI Carvedilol $pironolactone Micro Dextrose (Glucosa) Anhydrous N Aeetyl Glueosamine Amoxlcillin Na + Clavulonate K Cefaclor Monohidrate Sulpiride Diacethyl Naproxen Powder Ibuprofen Amoxicillin Na + Clavulonate K(5:1) Cefadroxil Compaeted Dielofenae Sodium Neutral Pellets Idebenone T Amoxicillin Trihydrate Compacted Cefalexine Monohydrate Powder Difenhydramire Nisin Taerollmus Monohydrate Imiquimod Amoxlcillln
    [Show full text]
  • RIEMSER Group International Product List
    RIEMSER Group International Product List Product Active substance Presentation Indication Product Category Channel EMB Fatol Ethambutol • POI 1g/10ml Treatment of several forms and stages of Anti-infectives Rx dihydrochloride • TAB 100mg tuberculosis • FCT 400, 500 mg Eremfat Rifampicin • GRA 1.2g/60ml Anti-infectives Rx • POI 300, 600mg Tuberculosis therapy , combination treatment of • FCT 150, 300, 450, 600 leprosy, prophylaxis for meningococcal meningitis, treatment of infections caused by nontuberculous mycobacteria Isozid Isoniazid • TAB 50, 100, 200 mg During Chemotherapy, -prophylaxis and - Anti-infectives Rx • POI 500mg prevention for / of tuberculosis Isozidcomp Isoniazid / pyridoxine • TAB 100mg / 20mg Chemotherapy, -prophylaxis and -prevention for / Anti-infectives Rx • FCT 200mg /40 mg, 300mg/60mg of Tuberculosis PAS-Fatol Sodium aminosalicylate • POI 13.49g Chemotherapy for tuberculosis, caused by Anti-infectives Rx dihydrate mycobacterium tuberculosis and mycobacterium bovis. Peteha Protionamide • FCT 250mg Treatment of tuberculosis, leprosy and diseases Anti-infectives Rx caused by so-called ubiquitours (atypical) mycobacteria Pyrafat Pyrazinamide • FCT 500mg Combination therapy for all types of tuberculosis, Anti-infectives Rx • TAB 500mg caused by mycobacterium tuberculosis, mycobacterium africanum, or mycobacterium microtti. Terizidon Terizidone • CAP 250mg Treatment of tuberculosis caused by Anti-infectives Rx mycobacterium tuberculosis Vancomycin Enterocaps Vancomycin • CAP 250 mg Treatment of certain types of bowel
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • EAR, NOSE and OROPHARYNX Updated: October 2020
    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
    [Show full text]
  • Ear, Nose and Oral Cavity
    NHS Borders Joint Prescribing Formulary Ear, nose, and oral cavity Black Text Drugs which may be prescribed by all prescribers Drugs which are either for specialist only prescription or for specialist Pink Text initiation, with prescribing transfer to GP Important Information: In addition to the disclaimer on NHS Borders website the following information is included confirming that the information contained in NHS Borders Joint Prescribing formulary is drawn from several sources, including BNF & BNF for children, product SPCs, local and national guidelines, local expert opinion, Lothian Joint Formulary and these are all gratefully acknowledged here. NHS Borders has done its utmost to ensure the information in the BJF is accurate and reliable, but NHS Borders cannot guarantee that the information is complete and accurate. Prescribers are referred to the SPCs, BNF and BNF for children to confirm prescribing information. June 2021 Contents Page Table of Contents 12.1 Drugs acting on the ear ................................................................................................ 3 Otitis externa ................................................................................................................ 3 Otitis media .................................................................................................................. 3 Removal of ear wax ..................................................................................................... 3 12.2 Drugs acting on the nose ............................................................................................
    [Show full text]
  • Medicines Formulary
    MEDICINES FORMULARY Medicines formulary between MCHFT and Primary Care as agreed by the Joint Medicines Management Group Welcome to the MCHFT Medicines Formulary. The formulary includes medicines that have been approved by the Joint Medicines Management Group (JMMG) for prescribing within the trust. The purpose of the formulary is to ensure prescribing is evidence based and cost effective. All prescribing within the trust (i.e. inpatient, outpatient and FP10HNC prescribing) must comply with the formulary. This will be monitored on a regular basis. Some drugs may appear in more than one section. Information on prescribing in primary care is available via the Medicines Management Team website: http://www.centralandeasterncheshiremmt.nhs.uk This is a good point of reference to confirm the continuation of medicines in primary care after initiation at MCHFT. The formulary is arranged in sections corresponding to those in the British National Formulary (BNF) as below; INTRODUCTION .......................................................................................................................................... 2 UPDATES TO THE FORMULARY (LAST UPDATED MAY 2019)............................................................... 4 1. GASTRO-INTESTINAL SYSTEM ............................................................................................................. 7 2. CARDIOVASCULAR SYSTEM .............................................................................................................. 11 3. RESPIRATORY SYSTEM .....................................................................................................................
    [Show full text]
  • An LC/MS-MS Screening Method for Synthetic Glucocorticoids Based on Pharmacological Structure-Activity Relationships
    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (14). Sport und Buch Strauß - Köln 2006 Monica Mazzarino, Maria Cristina Braganò, Francesco Botrè An LC/MS-MS screening method for synthetic glucocorticoids based on pharmacological structure-activity relationships Laboratorio Antidoping, Federazione Medico-Sportiva Italiana, Roma, Italy INTRODUCTION The last few years have shown a remarkable evolution of the approach utilized at an international level to control the abuse of drugs in sport. A series of preventive actions have been put in place by the World Anti-Doping Agency (WADA) to deter the illicit use of performance-enhancing agents. These actions are complementary to the traditional activity of the anti-doping laboratories, which remains a key component of any effective anti-doping policy. At the same time, there has been recent discovery of “designer steroids” [1-2] and, more generally, other previously unknown substances endowed with pharmacologically properties, specifically designed and synthesized with the aim of improving sport performance without the risk of being caught through anti-doping control. This has resulted in a more or less pronounced revision of analytical screening protocols to allow also the detection of those novel “designer drugs”. These compounds were not originally included in the WADA prohibited list, the international reference document detailing all the substances and methods forbidden for use by athletes [3]. This situation has led to the development of alternative analytical methods capable of detecting the presence of one or more drugs in human urine belonging to the same class of congeners, based on the recognition of common portions of the molecular structure.
    [Show full text]
  • Connectivity Map-Based Discovery of Parbendazole Reveals Targetable Human Osteogenic Pathway
    Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway Andrea M. Bruma, Jeroen van de Peppela, Cindy S. van der Leijea, Marijke Schreuders-Koedama, Marco Eijkenb, Bram C. J. van der Eerdena, and Johannes P. T. M. van Leeuwena,1 aDepartment of Internal Medicine, Erasmus MC, 3015 CN Rotterdam, The Netherlands; and bArcarios BV, 3015 CN Rotterdam, The Netherlands Edited by John T. Potts, Massachusetts General Hospital, Charlestown, MA, and approved September 4, 2015 (received for review January 26, 2015) Osteoporosis is a common skeletal disorder characterized by low molecules to a user’s selected gene signature of the phenotype bone mass leading to increased bone fragility and fracture suscepti- of interest using a pattern-matching algorithm with a high level bility. In this study, we have identified pathways that stimulate of resolution and specificity. The screening results in a list of differentiation of bone forming osteoblasts from human mesenchy- compounds with a highly correlating gene expression pattern to mal stromal cells (hMSCs). Gene expression profiling was performed that of the phenotype of interest, which has the potential to aid in hMSCs differentiated toward osteoblasts (at 6 h). Significantly in finding a novel treatment for a disease or to identify novel regulated genes were analyzed in silico, and the Connectivity Map pathways or genes involved in a complex biological process. To (CMap) was used to identify candidate bone stimulatory com- date, the CMap has been successfully used to identify compounds pounds. The signature of parbendazole matches the expression and combination therapies that show promise in the treatment of changes observed for osteogenic hMSCs.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]